Granite Bio develops first-in-class therapeutic antibodies targeting the fundamental biology of inflammation, autoimmunity, and fibrosis. The company's pipeline includes assets designed to selectively deplete pathogenic cells, such as GRT-001 which targets pro-inflammatory monocytes. These novel mechanisms aim to provide efficacious treatment options where current therapies are lacking for chronic inflammatory diseases.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with autoimmune, inflammatory, and fibrotic conditions often lack effective treatment options for chronic inflammatory diseases, which are a leading cause of death globally. Current therapies may not target the fundamental disease biology, limiting their efficacy.
Solution
Granite Bio is developing first-in-class therapeutic antibodies designed to target fundamental disease biology in inflammation, autoimmunity, and fibrosis. Their approach focuses on selectively depleting pathogenic cells to enhance therapeutic efficacy. Granite Bio's assets, including GRT-001 and GRT-002, are designed to target emerging central disease biology nodes. GRT-001 depletes pathogenic pro-inflammatory monocytes via ADCC/ADCP, acting as a first-in-class "Innate Rituximab." GRT-002 targets a novel therapeutic target identified through proprietary patient profiling, addressing a novel disease biology node in inflammation, autoimmunity, and fibrosis.
Target Audience
Granite Bio's therapies target patients with autoimmune, inflammatory, and fibrotic conditions.
Features
- GRT-001: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP
- GRT-001: First-in-class »Innate Rituximab«
- GRT-002: Targets a novel therapeutic target identified through proprietary patient profiling
- GRT-002: Addresses a novel disease biology node in inflammation, autoimmunity and fibrosis